In 2011, key trials with oral factor Xa inhibitors in patients with atrial fibrillation highlighted promising data on these novel anticoagulants. Patients with ≥1 stroke risk factors can be considered for oral anticoagulation. These novel, fixed-dose drugs are given without monitoring, so clinicians must learn to balance stroke and bleeding risks.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study
Cardiovascular Diabetology Open Access 10 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Connolly, S. J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806–817 (2011).
Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).
Lip, G. Y., Frison, L., Halperin, J. L. & Lane, D. A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 57, 173–180 (2011).
Olesen, J. B. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb. Haemost. 106, 739–749 (2011).
Ahrens, I., Lip, G. Y. & Peter, K. New oral anticoagulant drugs in cardiovascular disease. Thromb. Haemost. 104, 49–60 (2010).
Karthikeyan, G. & Eikelboom, J. W. The CHADS2 score for stroke risk stratification in atrial fibrillation—friend or foe? Thromb. Haemost. 104, 45–48 (2010).
Lip, G. Y. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J. Thromb. Haemost. 9 (Suppl. 1), 344–351 (2011).
Lip, G. Y. H. et al. Bleeding risk assessment and management in atrial fibrillation patients: executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb. Haemostat. 106, 997–1011 (2011).
Lip, G. Y. The role of aspirin for stroke prevention in atrial fibrillation. Nat. Rev. Cardiol. 8, 602–606 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
G. Y. H. Lip is or has been a consultant for the following companies: Astellas, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Merck, Portola Pharmaceuticals, and Sanofi. Additionally, he is or has been on the speakers bureau for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Sanofi. G. Y. H. Lip is also a director for focusAF, a nonprofit independent limited company, which has the objective of promoting independent medical education in atrial fibrillation.
Rights and permissions
About this article
Cite this article
Lip, G. Stroke prevention in AF. Nat Rev Cardiol 9, 71–73 (2012). https://doi.org/10.1038/nrcardio.2011.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.203
This article is cited by
-
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study
Cardiovascular Diabetology (2020)
-
Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Cardiovascular Drugs and Therapy (2013)